Westlake Village-based biotech company MannKind grew its revenue 184 percent for its first quarter to $3.4 million, but net losses still mounted, reaching $30.4 million, nearly double its loss for the same period in 2017. The increase comes from sales of its inhalable insulin product Afrezza, and it adopted a new accounting standard to measure…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
